{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:40:13Z","timestamp":1792521613960,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The pathogenesis and clinical consequences of viral blips are not completely understood. The aim of this large nationwide study was to investigate the incidence of viral blips and factors associated with them, with particular attention to the third (core) agent class\u2014comparing integrase strand transfer inhibitor (INSTI)-based regimens with non-nucleoside reverse transcriptase inhibitor (NNRTI)- and protease inhibitor (PI)-based regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From the Swedish national InfCareHIV cohort, we included treatment-na\u00efve adults who commenced antiretroviral therapy (ART) from 1 January 2007; data were extracted on 30 September 2020. Viral blips were defined as transient plasma HIV RNA levels between 50 and 500 copies\/mL preceded and followed by HIV RNA\u2009&lt;\u200950 copies\/mL. Virological failure was defined as two consecutive HIV RNA samples\u2009&gt;\u2009200 copies\/mL or a single sample of HIV RNA\u2009&gt;\u20091,000 copies\/mL, in previously suppressed individuals with more than 12\u2009months since ART initiation. Cox regression was used for event analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 4,210 individuals were included, of whom 853 (20.3%) had 1\u20146 registered blips. Median observation time was 5.5\u2009years (range 0.5\u201413.7). Blip incidence was 4.35 (95% CI 4.02\u20144.69) per 100 person-years. In a sensitivity analysis applying the narrower definition of 50\u2014199 copies\/mL, the incidence was 3.80 (95% CI 3.49\u20144.11) per 100 person-years. Individuals on INSTIs and NNRTIs had similar risk, while those on PIs had a significantly higher risk of blips (hazard ratio [HR] 1.22, 95% CI 1.03\u20141.45;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Transient viremia was not associated with an increased risk of subsequent virological failure; individuals with blips had a lower risk than those with continuously undetectable HIV RNA (HR 0.54, 95% CI 0.41\u20140.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Individuals on INSTI- and NNRTI-based ART had fewer viral blips than those on PI-based ART. In this cohort, transient viremia below 500 HIV RNA copies\/mL was not associated with a higher risk of subsequent virological failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-14654-z","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:56:44Z","timestamp":1792195004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding viral blips in people with HIV on antiretroviral therapy: a nationwide Swedish cohort study of 4,210 individuals"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-7485","authenticated-orcid":false,"given":"Erik","family":"S\u00f6rstedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"S\u00f6nnerborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Carlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Johan","family":"Treutiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"M\u00e5nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"\u00c4nghagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"9","key":"14654_CR1","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1086\/496985","volume":"41","author":"S Sungkanuparph","year":"2005","unstructured":"Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis. 2005;41(9):1326\u201332. https:\/\/doi.org\/10.1086\/496985.","journal-title":"Clin Infect Dis"},{"key":"14654_CR2","doi-asserted-by":"publisher","unstructured":"S\u00f6rstedt E, Nilsson S, Blaxhult A, Gissl\u00e9n M, Flamholc L, S\u00f6nnerborg A, et al. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. BMC Infect Dis. 2016;16(1). https:\/\/doi.org\/10.1186\/s12879-016-1628-6.","DOI":"10.1186\/s12879-016-1628-6"},{"issue":"12","key":"14654_CR3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1097\/00002030-200208160-00008","volume":"16","author":"JM Raboud","year":"2002","unstructured":"Raboud JM, Rae S, Woods R, Harris M, Montaner JSG. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. Aids. 2002;16(12):1627\u201332. https:\/\/doi.org\/10.1097\/00002030-200208160-00008.","journal-title":"Aids"},{"issue":"2","key":"14654_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.COH.0000203834.24221.13","volume":"1","author":"RE Nettles","year":"2006","unstructured":"Nettles RE, Kieffer TL. Update on HIV-1 viral load blips. Curr Opin HIV AIDS. 2006;1(2):157\u201361. https:\/\/doi.org\/10.1097\/01.COH.0000203834.24221.13.","journal-title":"Curr Opin HIV AIDS"},{"issue":"10","key":"14654_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1097\/01.aids.0000174453.55627.de","volume":"19","author":"V Martinez","year":"2005","unstructured":"Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, Gorin I, et al. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. Aids. 2005;19(10):1065\u201369. https:\/\/doi.org\/10.1097\/01.aids.0000174453.55627.de.","journal-title":"Aids"},{"issue":"7","key":"14654_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1177\/135965350801300707","volume":"13","author":"AM Geretti","year":"2008","unstructured":"Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7):927\u201336. https:\/\/doi.org\/10.1177\/135965350801300707.","journal-title":"Antivir Ther"},{"issue":"1","key":"14654_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/cid\/ciac762","volume":"76","author":"O Elvstam","year":"2023","unstructured":"Elvstam O, Malmborn K, El\u00e9n S, Marrone G, Garcia F, Zazzi M, et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort. Clin Infect Dis. 2023;76(1):25\u201331. https:\/\/doi.org\/10.1093\/cid\/ciac762.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"14654_CR8","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/cid\/ciz936","volume":"70","author":"TA Crowell","year":"2020","unstructured":"Crowell TA, Pinyakorn S, Sacdalan C, Kroon E, Colby DJ, Puttamaswin S, et al. Viral blips after treatment initiation during acute human immunodeficiency virus infection. Clin Infect Dis. 2020;70(12):2706\u201309. https:\/\/doi.org\/10.1093\/cid\/ciz936.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"14654_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1001\/jama.286.2.171","volume":"286","author":"DV Havlir","year":"2001","unstructured":"Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. J Am Med Assoc. 2001;286(2):171\u201379.","journal-title":"J Am Med Assoc"},{"issue":"19","key":"14654_CR10","doi-asserted-by":"publisher","first-page":"10566","DOI":"10.1128\/JVI.78.19.10566-10573.2004","volume":"78","author":"M Di Mascio","year":"2004","unstructured":"Di Mascio M, Markowitz M, Louie M, Hurley A, Hogan C, Simon V, et al. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol. 2004;78(19):10566\u201373. https:\/\/doi.org\/10.1128\/JVI.78.19.10566-10573.2004.","journal-title":"J Virol"},{"issue":"7","key":"14654_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jama.293.7.817","volume":"293","author":"RE Nettles","year":"2005","unstructured":"Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. J Am Med Assoc. 2005;293(7):817\u201329.","journal-title":"J Am Med Assoc"},{"key":"14654_CR12","doi-asserted-by":"publisher","unstructured":"Lima VD, Wang L, Brumme C, Wu L, Montaner JSG, Harrigan PR. Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification. PLoS One. 2017;12(2):e0171155. https:\/\/doi.org\/10.1371\/journal.pone.0171155.","DOI":"10.1371\/journal.pone.0171155"},{"issue":"1","key":"14654_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/QAI.0b013e3182487a20","volume":"60","author":"IC-H Fung","year":"2012","unstructured":"Fung IC-H, Gambhir M, van Sighem A, de Wolf F, Garnett GP. The clinical interpretation of viral blips in HIV patients receiving antiviral treatment: are we ready to infer poor adherence? J Acquir Immune Defic Syndr. 2012;60(1):5\u201311. https:\/\/doi.org\/10.1097\/QAI.0b013e3182487a20.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"14654_CR14","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1086\/523704","volume":"196","author":"TJ Podsadecki","year":"2007","unstructured":"Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis. 2007;196(12):1773\u201378. https:\/\/doi.org\/10.1086\/523704.","journal-title":"J Infect Dis"},{"issue":"1","key":"14654_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcv.2010.06.004","volume":"49","author":"D Sizmann","year":"2010","unstructured":"Sizmann D, Glaubitz J, Simon CO, Goedel S, Buergisser P, Drogan D, et al. Improved HIV-1 RNA quantitation by COBAS\u00ae AmpliPrep\/COBAS\u00ae TaqMan\u00ae HIV-1 test, v2.0 using a novel dual-target approach. J Clin Virol. 2010;49(1):41\u201346. https:\/\/doi.org\/10.1016\/j.jcv.2010.06.004.","journal-title":"J Clin Virol"},{"issue":"1","key":"14654_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2012.10.004","volume":"187","author":"CM Wojewoda","year":"2013","unstructured":"Wojewoda CM, Spahlinger T, Harmon ML, Schnellinger B, Li Q, Dejelo C, et al. Comparison of Roche Cobas AmpliPrep\/Cobas TaqMan HIV-1 test version 2.0 (CAP\/CTM v2.0) with other real-time PCR assays in HIV-1 monitoring and follow-up of low-level viral loads. J Virol Methods. 2013;187(1):1\u20135. https:\/\/doi.org\/10.1016\/j.jviromet.2012.10.004.","journal-title":"J Virol Methods"},{"issue":"8","key":"14654_CR17","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/infdis\/jis104","volume":"205","author":"JT Grennan","year":"2012","unstructured":"Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis. 2012;205(8):1230\u201338. https:\/\/doi.org\/10.1093\/infdis\/jis104.","journal-title":"J Infect Dis"},{"issue":"1","key":"14654_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12879-020-4837-y","volume":"20","author":"T Zhang","year":"2020","unstructured":"Zhang T, Ding H, An M, Wang X, Tian W, Zhao B, et al. Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort. BMC Infect Dis. 2020;20(1):147. https:\/\/doi.org\/10.1186\/s12879-020-4837-y.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"14654_CR19","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/cid\/ciz129","volume":"69","author":"C Joya","year":"2019","unstructured":"Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, et al. Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure. Clin Infect Dis. 2019;69(12):2145\u201352. https:\/\/doi.org\/10.1093\/cid\/ciz129.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"14654_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/hiv.12431","volume":"18","author":"M Gisslen","year":"2017","unstructured":"Gisslen M, Svedhem V, Lindborg L, Flamholc L, Norrgren H, Wendahl S, et al. Sweden, the first country to achieve the Joint United Nations Programme on HIV\/AIDS (Unaids)\/world Health Organization (WHO) 90-90-90 continuum of HIV care targets. HIV Med. 2017;18(4):305\u201307. https:\/\/doi.org\/10.1111\/hiv.12431.","journal-title":"HIV Med"},{"key":"14654_CR21","doi-asserted-by":"publisher","unstructured":"Marrone G, Mellgren \u00c5, Eriksson LE, Svedhem V. High concordance between self-reported adherence, treatment outcome and satisfaction with care using a nine-item health questionnaire in InfCareHIV. PLoS One. 2016;11(6):e0156916. https:\/\/doi.org\/10.1371\/journal.pone.0156916.","DOI":"10.1371\/journal.pone.0156916"},{"key":"14654_CR22","unstructured":"Stanford University HIV Drug Resistance Database. Hivdb algorithm version 8.9-1. Stanford, CA: Stanford University. https:\/\/hivdb.stanford.edu."},{"issue":"4","key":"14654_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/cid\/ciad219","volume":"77","author":"H \u00c1lvarez","year":"2023","unstructured":"\u00c1lvarez H, Mocroft A, Ryom L, Neesgaard B, Edwards S, Svedhem V, et al. Plasma human immunodeficiency virus 1 RNA and CD4+ T-Cell counts are determinants of virological nonsuppression outcomes with initial integrase inhibitor-based regimens: a prospective RESPOND cohort study. Clin Infect Dis. 2023;77(4):593\u2013605. https:\/\/doi.org\/10.1093\/cid\/ciad219.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"14654_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1093\/jac\/dky467","volume":"74","author":"V Joly","year":"2019","unstructured":"Joly V, Burdet C, Landman R, Vigan M, Charpentier C, Katlama C, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74(3):739\u201345. https:\/\/doi.org\/10.1093\/jac\/dky467.","journal-title":"J Antimicrob Chemother"},{"key":"14654_CR25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jcv.2018.06.012","volume":"105","author":"S Rusconi","year":"2018","unstructured":"Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, et al. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): durability and virological response in a large Italian HIV drug resistance network (ARCA). J Clin Virol. 2018;105:112\u201317. https:\/\/doi.org\/10.1016\/j.jcv.2018.06.012.","journal-title":"J Clin Virol"},{"issue":"7","key":"14654_CR26","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1093\/jac\/dky093","volume":"73","author":"JL Blanco","year":"2018","unstructured":"Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018;73(7):1965\u201371. https:\/\/doi.org\/10.1093\/jac\/dky093.","journal-title":"J Antimicrob Chemother"},{"key":"14654_CR27","doi-asserted-by":"publisher","unstructured":"Olearo F, Nguyen H, Bonnet F, Yerly S, Wandeler G, Stoeckle M, et al. Impact of the M184V\/I mutation on the efficacy of abacavir\/lamivudine\/dolutegravir therapy in HIV treatment-experienced patients. Open Forum Infect Dis. 2019;6(10):ofz330. https:\/\/doi.org\/10.1093\/ofid\/ofz330.","DOI":"10.1093\/ofid\/ofz330"},{"issue":"5","key":"14654_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/QAI.0000000000002898","volume":"89","author":"S Dijkstra","year":"2022","unstructured":"Dijkstra S, Hofstra LM, Mudrikova T, Wensing AMJ, Oomen PGA, Hoepelman AIM, et al. Lower incidence of HIV-1 blips observed during integrase inhibitor\u2013based combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2022;89(5):575\u201382. https:\/\/doi.org\/10.1097\/QAI.0000000000002898.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"14654_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1468-1293.2012.01012.x","volume":"13","author":"G Martin-Blondel","year":"2012","unstructured":"Martin-Blondel G, Saune K, Vu Hai V, Marchou B, Delobel P, Izopet J, et al. Factors associated with a strictly undetectable viral load in HIV-1-infected patients. HIV Med. 2012;13(9):568\u201373. https:\/\/doi.org\/10.1111\/j.1468-1293.2012.01012.x.","journal-title":"HIV Med"},{"key":"14654_CR30","doi-asserted-by":"publisher","unstructured":"Hofstra LM, Mudrikova T, Stam AJ, Otto S, Tesselaar K, Nijhuis M, et al. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients. PLoS One. 2014;9(10):e110749. https:\/\/doi.org\/10.1371\/journal.pone.0110749.","DOI":"10.1371\/journal.pone.0110749"},{"key":"14654_CR31","doi-asserted-by":"publisher","unstructured":"Oomen PGA, Dijkstra S, Hofstra LM, Nijhuis MM, Verbon A, Mudrikova T, et al. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: results from a retrospective cohort study. J Med Virol. 2023;95(10):e29178. https:\/\/doi.org\/10.1002\/jmv.29178.","DOI":"10.1002\/jmv.29178"},{"issue":"3","key":"14654_CR32","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/cid\/ciaf103","volume":"81","author":"TA Crowell","year":"2025","unstructured":"Crowell TA, Hsieh HC, Wang X, Chu X, Gayle B, Berjohn CM, et al. Antiretroviral therapy within 2 years of HIV acquisition is associated with fewer viral blips: a retrospective analysis of more than 20 years of data from the US military HIV natural history study. Clin Infect Dis. 2025;81(3):499\u2013509. https:\/\/doi.org\/10.1093\/cid\/ciaf103.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"14654_CR33","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1086\/590943","volume":"47","author":"R Gupta","year":"2008","unstructured":"Gupta R, Hill A, Sawyer AW, Pillay D. Emergence of drug resistance in HIV type 1\u2013infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis. 2008;47(5):712\u201322. https:\/\/doi.org\/10.1086\/590943.","journal-title":"Clin Infect Dis"},{"key":"14654_CR34","unstructured":"Referensgruppen f\u00f6r Antiviral Terapi (RAV). Antiretroviral treatment for HIV infection: Swedish recommendations 2019. In: The Swedish Society of Medicine. 2019."},{"issue":"1","key":"14654_CR35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1742-6405-2-2","volume":"2","author":"HA Baird","year":"2005","unstructured":"Baird HA, Marozsan AJ, Lederman MM, Landay A, Mildvan D, Kuritzkes DR, et al. Monitoring processed, mature human immunodeficiency virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther. 2005;2(1):2. https:\/\/doi.org\/10.1186\/1742-6405-2-2.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"14654_CR36","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41467-019-10884-9","volume":"10","author":"N Bachmann","year":"2019","unstructured":"Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun. 2019;10(1):3193. https:\/\/doi.org\/10.1038\/s41467-019-10884-9.","journal-title":"Nat Commun"},{"key":"14654_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jtbi.2014.06.042","volume":"360","author":"S Wang","year":"2014","unstructured":"Wang S, Rong L. Stochastic population switch may explain the latent reservoir stability and intermittent viral blips in HIV patients on suppressive therapy. J Theor Biol. 2014;360:137\u201348. https:\/\/doi.org\/10.1016\/j.jtbi.2014.06.042.","journal-title":"J Theor Biol"},{"key":"14654_CR38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jtbi.2015.02.001","volume":"371","author":"D S\u00e1nchez-Taltavull","year":"2015","unstructured":"S\u00e1nchez-Taltavull D, Alarc\u00f3n T. Stochastic modelling of viral blips in HIV-1-infected patients: effects of inhomogeneous density fluctuations. J Theor Biol. 2015;371:79\u201389. https:\/\/doi.org\/10.1016\/j.jtbi.2015.02.001.","journal-title":"J Theor Biol"},{"issue":"1","key":"14654_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jcv.2004.11.012","volume":"33","author":"B Masquelier","year":"2005","unstructured":"Masquelier B, Pereira E, Peytavin G, Descamps D, Reynes J, Verdon R, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol. 2005;33(1):75\u201378. https:\/\/doi.org\/10.1016\/j.jcv.2004.11.012.","journal-title":"J Clin Virol"},{"issue":"3","key":"14654_CR40","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/hiv.12413","volume":"18","author":"R Teira","year":"2017","unstructured":"Teira R, Vidal F, Mu\u00f1oz-S\u00e1nchez P, Geijo P, Viciana P, Ribera E, et al. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients. HIV Med. 2017;18(3):196\u2013203. https:\/\/doi.org\/10.1111\/hiv.12413.","journal-title":"HIV Med"},{"key":"14654_CR41","doi-asserted-by":"publisher","unstructured":"Longo S, Bon I, Musumeci G, Bertoldi A, D\u2019urbano V, Calza L, et al. Comparison of the Aptima HIV-1 Quant Dx assay with the COBAS AmpliPrep\/COBAS TaqMan HIV-1 v2.0 test for HIV -1 viral load quantification in plasma samples from HIV-1\u2013infected patients. Health Sci Rep. 2018;1(4):e31. https:\/\/doi.org\/10.1002\/hsr2.31.","DOI":"10.1002\/hsr2.31"},{"issue":"6","key":"14654_CR42","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1128\/JCM.00288-14","volume":"52","author":"A Amendola","year":"2014","unstructured":"Amendola A, Marsella P, Bloisi M, Forbici F, Angeletti C, Capobianchi MR. Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep\/Cobas TaqMan HIV-1 version 2.0) to quantify low HIV-1 RNA levels (<1, 000 copies\/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays. J Clin Microbiol. 2014;52(6):2019\u201326. https:\/\/doi.org\/10.1128\/JCM.00288-14.","journal-title":"J Clin Microbiol"},{"key":"14654_CR43","doi-asserted-by":"publisher","unstructured":"Hermans LE, Carmona S, Nijhuis M, Tempelman HA, Richman DD, Moorhouse M, et al. Virological suppression and clinical management in response to viremia in South African HIV treatment program: a multicenter cohort study. PLoS Med. 2020;17(2):e1003037. https:\/\/doi.org\/10.1371\/journal.pmed.1003037.","DOI":"10.1371\/journal.pmed.1003037"},{"key":"14654_CR44","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach - second edition. http:\/\/apps.who.int\/iris\/bitstream\/10665\/208825\/1\/9789241549684_eng.pdf?ua=1."},{"key":"14654_CR45","doi-asserted-by":"publisher","unstructured":"S\u00f6rstedt E, Nduva G, M\u00e5nsson F, Mellgren \u00c5, Repits J, Fernvik E, et al. Comparative effectiveness of dolutegravir + lamivudine versus three-drug regimens in Swedish clinical practice: a nationwide study. J Int AIDS Soc. 2026;29(3):e70054. https:\/\/doi.org\/10.1002\/jia2.70054.","DOI":"10.1002\/jia2.70054"},{"issue":"6","key":"14654_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/idr17060141","volume":"17","author":"K Yamaguchi","year":"2025","unstructured":"Yamaguchi K, Ishihara M, Ikoma Y, Sugiyama H, Watanabe D, Fujita K, et al. A comparison of the risk of viral load blips in human immunodeficiency virus patients on two-drug versus three-drug antiretroviral regimens. Infect Dis Rep. 2025;17(6):141. https:\/\/doi.org\/10.3390\/idr17060141.","journal-title":"Infect Dis Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14654-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14654-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-14654-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:02:38Z","timestamp":1792519358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-14654-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14654"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-14654-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"1 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Review Board in Gothenburg, Sweden (Dnr: 532\u201311). It used only retrospective, de-identified data from InfCareHIV, a national quality registry in which individuals are informed that their data may be used for research and may decline registration or have their data erased at any time (Swedish Patient Data Act, SFS 2008:355, Chapter 7). The Review Board approved the study without a requirement for additional individual consent.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1835"}}